article thumbnail

Lung cancer deaths decline but.

World of DTC Marketing

In recent years, early detection and treatment improvements have helped boost the 3-year survival rate for lung cancer from 21% in 2004 to 31% in 2015 through 2017. But it’s still the leading cause of cancer deaths. Although lung cancer’s mortality rate has fallen, the disease is still the leading cause of cancer deaths.

Medicine 271
article thumbnail

European Commission revokes marketing authorisation for Novartis’ crizanlizumab

European Pharmaceutical Review

Novartis said the decision to revoke the authorisation was based on a review of crizanlizumab under Article 20 of Regulation (EC) No 726/2004. EMA required the STAND study as part of the marketing authorisation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Teva appoints Eric Hughes as head of R&D and Chief Medical Officer

European Pharmaceutical Review

At the beginning of his career in 2004, Dr Hughes was responsible for early clinical research at Bristol Myers-Squibb Company and then at Schering-Plough Research Institute. ” Since September 2021, Dr Hughes has been Senior Vice President of Clinical Development and Translational Medicine at Vertex Pharmaceuticals, based in Boston. .”

Medical 98
article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

4,6 Traditional Herbal Registration The Traditional Herbal Medicines Directive (Directive 2004/24/EC) is implemented in the UK by the Medicines (Traditional Herbal Medicinal Products for Human Use) Regulations 2005 and came into force on 30 April 2011. 13 Currently, over 350 herbal remedies have been granted a THR licence. 2012/1916).

Marketing 103
article thumbnail

Astellas and Bayer announce management changes

European Pharmaceutical Review

Since joining Astellas Group (former Yamanouchi Group) in 2004, he has held various positions including Regional Senior Vice President, North Europe, Astellas Pharma Europe Ltd. He is the ideal candidate to lead Bayer… at a time of a disruptive innovation cycle in biology, chemistry and artificial intelligence.

article thumbnail

Pharmaceutical industry: 2023 in retrospect

European Pharmaceutical Review

During 2023, there were five revisions to the European Medicines Agency ’s (EMA’s) Questions and Answers (Q&As) for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products. 2004; 29: 100298. J Pharm Sci.

article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

This suggests that any of the modelled changes to the regulation could lead to a decrease in the number of OMPs developed… Some of the assessed changes to the regulation could undermine the business model under which OMP?focused THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION; 2004.